MetaCap

Celularity (CELU) vs Psyence Biomedical (PBM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Celularity (CELU) has outperformed Psyence Biomedical (PBM) over the past year, losing 73.5% versus a loss of 94.9%. Psyence Biomedical is the larger company by market cap ($15.8 million vs $15.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CELU-73.54%PBM-94.90%
+27%-37%-102%
Nov 21, 20251 yearNov 20, 2026
CELU-99.18%PBM-100.00%
+127%+8%-111%
Dec 6, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CELU versus PBM key metrics
MetricCELUPBM
Share price$0.463$2.97
Market cap$15.02M$15.80M
1-day change-1.05%+3.85%
YTD return-58.29%-89.90%
1-year return-73.54%-94.90%
5-year return-99.31%—
EPS (TTM)$-1.69$-12.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$26.55M—
Revenue growth (YoY)-51.03%—
Net income (latest FY)$-91.72M$1.01M
Gross margin24.39%—
Operating margin-230.92%—
Net margin-345.45%—
52-week high$2.55$73.44
52-week low$0.42$1.92
Distance from 52-week high-81.84%-95.96%
Average volume3.95M61.93K
Shares outstanding32.45M5.32M
Employees11512
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CELU has outperformed PBM by 21.4 percentage points over the past year.

About Celularity

CELU stock →

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.

Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees

About Psyence Biomedical

PBM stock →

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

CELU vs PBM FAQ

Which is bigger, Celularity or Psyence Biomedical?

Psyence Biomedical (PBM) is larger, with a market capitalization of $15.80M compared with $15.02M for Celularity (CELU).

Which stock has performed better over the past year, CELU or PBM?

CELU returned -73.54% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.

Are Celularity and Psyence Biomedical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons